NCT07796204Not yet recruiting
Ability of Almonds to Improve Nutrition During GLP-1 Treatment
The Ability of Almonds to Increase Vitamin E (Alpha-tocopherol) and Diet Quality During GLP-1 Treatment: A Randomized Controlled Pilot Trial
Source: ClinicalTrials.gov · Last updated 1 Sept 2026
Brief summary (registry, in English)
This 8-week randomized controlled pilot trial is to test the hypothesis that, compared to a Usual Diet control group, almond intake will increase vitamin E (alpha-tocopherol) levels in the blood and improve diet quality (Healthy Eating Index) among people prescribed a glucagon-like peptide-1. Two groups of individuals will either: 1) consume a minimum of 56 grams of almonds each day, or 2) not consume almonds and follow their usual diet.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 76 (estimated)
- First submitted
- 27 Aug 2026
- Start date
- Sept 2026
- Primary completion date
- Jun 2028
- Lead sponsor
- Pennington Biomedical Research Center
- Diseases
- Obesity, Type 2 diabetes
- NCT number
- NCT07796204
What you commit to
- Study type: Interventional
- Planned participants: 76
- From Sept 2026 to the primary completion date, Jun 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Taking or planning to take during the trial a medication, vitamin, or mineral supplement that affects vitamin E levels
- Previous use of a glucagon-like peptide-1 medication in the last 3 months
- Contraindications to glucagon-like peptide-1 medication use or previous adverse reaction/allergy to a glucagon-like peptide-1 receptor agonist medication
Other illness
- Medical, psychological, cognitive, or other conditions that limit the ability to complete study procedure
- History of bariatric surgery
- Allergic to almonds
- Active malignancy, excluding some skin cancers, or undergoing chemotherapy/radiotherapy
Other
- Pregnancy or breastfeeding
Who the study is looking for
- Adults aged 18-70 years
- BMI ≥ 27 kg/m2 - 47.5 kg/m2 and diagnosed with type 2 diabetes by their personal physician (e.g., primary care physician, endocrinologist), or BMI ≥ 30 kg/m2 and have obesity and stable access (i.e., at least a two-month supply) to the medication
- Prescribed branded injectable semaglutide or injectable tirzepatide (medication will not be provided as part of the study)
- HbA1c will be measured at Pennington Biomedical at baseline (and follow-up), though the baseline HbA1c levels from Pennington Biomedical will not be used for eligibility criteria
- Use of other medications (diabetes medications or otherwise) are permitted at the discretion of the Medical Investigator
- Enroll and complete baseline assessments prior to starting pharmacotherapy
- Able and willing to adhere to all study-related procedures
Age in the registry: 18 years to 70 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Pennington Biomedical Research Center Coordinator of this site? Confirm its status | Baton Rouge | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.